FDA Approves LYTENAVA as First Ophthalmic Bevacizumab for Wet AMD
OTLK has more than doubled off its 52-week low of $0.161.
Summary
The FDA approved LYTENAVA for wet AMD, making it the first and only FDA-approved ophthalmic bevacizumab. This is a transformative event for Outlook Therapeutics, which had a going concern warning and minimal revenue. The approval grants 12 years of market exclusivity under BPCIA, creating a significant commercial opportunity. The drug is expected to be available to U.S. patients before year-end. This follows a series of dilutive financings and a successful appeal after an initial FDA setback. The approval removes the primary regulatory risk and opens a path to revenue generation in a large market.
At the time of this announcement, OTLK was trading at $1.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $305.7M. The 52-week trading range was $0.16 to $3.39. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Reuters.